These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 2154737

  • 1. Receptor binding properties of amperozide.
    Svartengren J, Simonsson P.
    Pharmacol Toxicol; 1990; 66 Suppl 1():8-11. PubMed ID: 2154737
    [Abstract] [Full Text] [Related]

  • 2. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action.
    Meltzer HY, Zhang Y, Stockmeier CA.
    Eur J Pharmacol; 1992 May 27; 216(1):67-71. PubMed ID: 1388121
    [Abstract] [Full Text] [Related]

  • 3. The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding.
    Svartengren J, Celander M.
    Eur J Pharmacol; 1994 Mar 11; 254(1-2):73-81. PubMed ID: 7911431
    [Abstract] [Full Text] [Related]

  • 4. Selective down-regulation of the agonist-dependent high affinity state of rat cortical 5-HT2 receptors following chronic treatment with amperozide.
    Svartengren JO.
    J Recept Res; 1993 Mar 11; 13(1-4):379-92. PubMed ID: 8450497
    [Abstract] [Full Text] [Related]

  • 5. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J, Pettersson E, Björk A.
    Biol Psychiatry; 1997 Aug 15; 42(4):247-59. PubMed ID: 9270901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biochemical and electrophysiological studies of the psychotropic compound, amperozide.
    Haskins JT, Muth EA, Andree TH.
    Brain Res Bull; 1987 Oct 15; 19(4):465-71. PubMed ID: 2825928
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ, Copinga S, Unelius L, Jackson DM, Wikström HV, Grol CJ.
    Bioorg Med Chem; 1999 Jul 15; 7(7):1263-71. PubMed ID: 10465402
    [Abstract] [Full Text] [Related]

  • 18. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography.
    Schotte A, de Bruyckere K, Janssen PF, Leysen JE.
    Brain Res; 1989 Oct 23; 500(1-2):295-301. PubMed ID: 2481562
    [Abstract] [Full Text] [Related]

  • 19. Studies on the receptor profile of bisoprolol.
    Klockow M, Greiner HE, Haase A, Schmitges CJ, Seyfried C.
    Arzneimittelforschung; 1986 Feb 23; 36(2):197-200. PubMed ID: 2870719
    [Abstract] [Full Text] [Related]

  • 20. Interaction of SM-3997 with serotonin receptors in rat brain.
    Shimizu H, Karai N, Hirose A, Tatsuno T, Tanaka H, Kumasaka Y, Nakamura M.
    Jpn J Pharmacol; 1988 Mar 23; 46(3):311-4. PubMed ID: 2898033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.